aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
Company profile
Ticker
LIFE
Exchange
Website
CEO
Sanjay Shukla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
LIFE stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
14 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Results of Operations and Financial Condition
9 Mar 23
PRE 14A
Preliminary proxy
7 Mar 23
8-K
Other Events
9 Feb 23
424B5
Prospectus supplement for primary offering
9 Feb 23
424B5
Prospectus supplement for primary offering
8 Feb 23
8-K
Other Events
6 Feb 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Results of Operations and Financial Condition
10 Nov 22
Transcripts
LIFE
Earnings call transcript
2022 Q4
9 Mar 23
LIFE
Earnings call transcript
2022 Q3
11 Nov 22
LIFE
Earnings call transcript
2022 Q2
16 Aug 22
LIFE
Earnings call transcript
2022 Q1
10 May 22
LIFE
Earnings call transcript
2021 Q4
15 Mar 22
LIFE
Earnings call transcript
2021 Q3
11 Nov 21
LIFE
Earnings call transcript
2021 Q2
11 Aug 21
LIFE
Earnings call transcript
2021 Q1
14 May 21
LIFE
Earnings call transcript
2020 Q4
24 Mar 21
LIFE
Earnings call transcript
2020 Q3
13 Nov 20
Latest ownership filings
SC 13G
LYTTON LAURENCE W
22 Feb 23
4
Sanjay Shukla
21 Feb 23
4
Jill Marie Broadfoot
21 Feb 23
4
NANCY DENYES
21 Feb 23
SC 13G/A
Stonepine Capital Management, LLC
17 Feb 23
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
NANCY DENYES
6 Feb 23
4
Jill Marie Broadfoot
6 Feb 23
4
Sanjay Shukla
6 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 13.15 mm | 13.15 mm | 13.15 mm | 13.15 mm | 13.15 mm | 13.15 mm |
| Cash burn (monthly) | 2.48 mm | (no burn) | 2.65 mm | 3.87 mm | 3.46 mm | 3.49 mm |
| Cash used (since last report) | 7.31 mm | n/a | 7.80 mm | 11.39 mm | 10.18 mm | 10.28 mm |
| Cash remaining | 5.83 mm | n/a | 5.34 mm | 1.76 mm | 2.97 mm | 2.87 mm |
| Runway (months of cash) | 2.3 | n/a | 2.0 | 0.5 | 0.9 | 0.8 |
Institutional ownership, Q4 2022
41.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 39 |
| Opened positions | 8 |
| Closed positions | 5 |
| Increased positions | 12 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 37.18 bn |
| Total shares | 22.04 mm |
| Total puts | 35.30 k |
| Total calls | 2.90 k |
| Total put/call ratio | 12.2 |
| Largest owners | Shares | Value |
|---|---|---|
| FHI Federated Hermes | 5.23 mm | $11.46 bn |
| FMR | 4.35 mm | $9.53 bn |
| Alyeska Investment | 1.38 mm | $3.02 bn |
| Tikvah Management | 1.35 mm | $2.96 bn |
| Aspire Capital Fund | 1.31 mm | $8.18 mm |
| Venrock Healthcare Capital Partners II | 1.17 mm | $0.00 |
| VR Adviser | 1.17 mm | $2.57 bn |
| Vanguard | 1.14 mm | $2.50 bn |
| Tang Capital Partners | 1.11 mm | $0.00 |
| Walleye Capital | 750.00 k | $1.64 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Feb 23 | Denyes Nancy | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.195 | 84,023 | 184.43 k | 84,023 |
| 16 Feb 23 | Broadfoot Jill Marie | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.195 | 84,023 | 184.43 k | 84,023 |
| 16 Feb 23 | Shukla Sanjay | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.195 | 336,096 | 737.73 k | 336,096 |
| 6 Feb 23 | Broadfoot Jill Marie | Common stock | Sell | Dispose S | No | No | 2.36 | 1,566 | 3.70 k | 15,460 |
| 3 Feb 23 | Shukla Sanjay | Common stock | Option exercise | Acquire M | No | No | 0 | 10,375 | 0.00 | 61,173 |
| 3 Feb 23 | Shukla Sanjay | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,375 | 0.00 | 31,125 |
| 3 Feb 23 | Broadfoot Jill Marie | Common stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 17,026 |
| 3 Feb 23 | Broadfoot Jill Marie | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,750 | 0.00 | 11,250 |
News
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
11 Mar 23
Stocks That Hit 52-Week Lows On Friday
10 Mar 23
Where aTyr Pharma Stands With Analysts
10 Mar 23
RBC Capital Reiterates Outperform on aTyr Pharma, Maintains $19 Price Target
10 Mar 23
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
10 Mar 23
Press releases
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
21 Mar 23
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
9 Mar 23
aTyr Pharma to Present at March Investor Conferences
8 Mar 23
aTyr Pharma Announces Commencement of Public Offering of Common Stock
8 Feb 23